Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gynecology | Nursing | Pediatrics | Pharmacy | Journal

Back to Journal Articles

No New Safety Concerns for Gardasil in Young Females

Last Updated: October 02, 2012.

 

No additional safety problems detected since its approval in 2006

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Since its approval in 2006, no new safety concerns have been found to be associated with vaccinating girls and young women with the quadrivalent human papillomavirus vaccine, Gardasil, according to a study published online Oct. 1 in the Archives of Pediatrics & Adolescent Medicine.

TUESDAY, Oct. 2 (HealthDay News) -- Since its approval in 2006, no new safety concerns have been found to be associated with vaccinating girls and young women with the quadrivalent human papillomavirus vaccine (HPV4), Gardasil, according to a study published online Oct. 1 in the Archives of Pediatrics & Adolescent Medicine.

As part of a post-licensure commitment to the U.S. Food and Drug Administration and the European Medicines Agency, Nicola P. Klein, M.D., Ph.D., from the Kaiser Permanente Vaccine Study Center in Oakland, Calif., and colleagues reviewed safety data from 189,629 females who received at least one dose of HPV4 from 2006 to 2008.

As determined by post-vaccination emergency department and hospitalization events, the researchers found that only skin infections up to day 14 (odds ratio, 1.8) and syncope on the day of vaccination (odds ratio, 6.0) were likely associated with vaccination with HPV4.

"The findings from this large, comprehensive study did not detect any evidence of serious safety concerns secondary to HPV4," Klein and colleagues conclude. "These findings support the general safety of routine vaccination with HPV4 to prevent cancer."

The study was funded by Merck, the manufacturer of Gardasil; several authors disclosed financial ties to pharmaceutical companies, including Merck.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: New Guidelines Issued for Management of Gout Next: Many Juvenile Detainees Have Psychiatric Disorders Later On

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.